Aseptically Prepared Systemic Anti-Cancer Therapy Medicines

This framework agreement, issued by the Mid South Essex NHS Foundation Trust under solicitation number PR-2264, establishes a long-term arrangement for the supply of aseptically prepared systemic anti-cancer therapy medicines. The scope of the contract includes the provision of batch manufactured drugs in ready-to-administer presentations and agreed dose bands, as well as the manufacturing and supply of patient-specific therapy drugs and medicines used in CIVAs. The agreement is structured across three distinct lots: Dose Banded Medicines, Patient Specific Medicines, and CIVAS. The contract was awarded on October 26, 2026, with an estimated duration of eight years, running from December 1, 2026, to November 30, 2034. While multiple suppliers were selected for the first two lots concerning dose banded and patient-specific medicines, Quantum Pharmaceutical Limited was specifically awarded the contract for Lot 3. This strategic framework ensures a consistent supply of critical oncology medications and specialized pharmaceutical services for the trust.